GLPwatch
Wegovy for Gastroparesis
semaglutide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCWegovy (semaglutide) is not FDA-approved for gastroparesis, and any use for this condition is off-label or investigational. The listed research examines semaglutide’s effects on gastric emptying and residual gastric content but does not establish its safety or efficacy for treating gastroparesis.
AI summary of the sources below.
| Drug | Wegovy (semaglutide) |
|---|---|
| Condition | Gastroparesis |
| Approval status | Investigational / off-label |
| Research papers | 11 |
Wegovy is not FDA-approved for gastroparesis; the research below reflects investigational or off-label study only.
Research on semaglutide for gastroparesis (11)
- Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report.
- Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound: a prospective observational study in volunteers without obesity recently started on semaglutide.
- Relationship between residual gastric content and peri-operative semaglutide use assessed by gastric ultrasound: a prospective observational study.
- Effect of various perioperative semaglutide interruption intervals on residual gastric content assessed by esophagogastroduodenoscopy: A retrospective single center observational study.
- Evaluation of gastric content in fasting patient during semaglutide use: an observational study.
- Effect of Swallow Balloon Therapy with the Combination of Semaglutide Oral Formulation: a Randomised Double-Blind Single-Centre Study.
- Comparing the risk of gastroparesis following different modalities for treating obesity: semaglutide versus bupropion-naltrexone versus sleeve gastrectomy - a retrospective cohort study.
- Semaglutide: A New Medical Swiss Army Knife?
- Gastrointestinal disorders potentially associated with Semaglutide: an analysis from the Eudravigilance Database.
- Acute gastric dilation associated with the use of semaglutide, a GLP-1 analogue.
- Association Between Semaglutide or Tirzepatide Therapy and Residual Gastric Content: A Potential Danger During Upper Endoscopy.